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Abstract
Common bile duct (CBD) stones are generally associated with greater elevations of alkaline phosphatase and gamma-glutamyl
transpeptidase levels than aspartate aminotransferase and alanine aminotransferase levels. However, some patients with CBD
stones showmarkedly increased aminotransferase levels, sometimes leading to the misdiagnosis of liver disease. Therefore, the aim
of this study was to investigate the clinicopathologic features of patients with CBD stones and high aminotransferase levels.
This prospective cohort study included 882 patients diagnosed with CBD stones using endoscopic retrograde
cholangiopancreatography (ERCP). Among these patients, 38 (4.3%) exhibited aminotransferase levels above 400 IU/L without
cholangitis (gallstone hepatitis [GSH] group), and 116 (13.2%) exhibited normal aminotransferase levels (control group). We
compared groups in terms of clinical features, laboratory test results, radiologic images, and ERCP ﬁndings such as CBD diameter,
CBD stone diameter and number, and periampullary diverticulum. Liver biopsy was performed for patients in the GSH group.
GSH patients were younger and more likely to have gallbladder stones than control patients, implying a higher incidence of
gallbladder stone migration. Also, GSH patients experienced more severe, short-lasting abdominal pain. ERCP showed narrower
CBDs in GSH patients than in control patients. Histological analysis of liver tissue fromGSH patients showed no abnormalities except
for mild inﬂammation.
Compared with control patients, GSH patients were younger and showedmore severe, short-lasting abdominal pain, which could
be due to a sudden increase of CBD pressure resulting from the migration of gallstones through narrower CBDs. These clinical
features could be helpful not only for the differential diagnosis of liver disease but also for investigating the underlying mechanisms of
liver damage in obstructive jaundice. Moreover, we propose a new deﬁnition of “gallstone hepatitis” based on the speciﬁc
clinicopathologic characteristics observed in our patients.
Abbreviations: ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, CBD =
common bile duct, ERCP = endoscopic retrograde cholangiopancreatography, g-GT = gamma-glutamyl transpeptidase, GSH =
gallstone hepatitis.
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11. Introduction
Precise interpretation of abnormalities in the results of liver
function tests is necessary for the diagnostic work-up for
hepatobiliary disease. In general, abnormalities in liver function
can be classiﬁed into 2 patterns: a hepatocellular pattern, in
which aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels are elevated higher than alkaline
phosphatase (ALP) and gamma-glutamyl transpeptidase
(g-GT) levels,[1] and a cholestatic pattern, in which ALP and
g-GT levels are elevated higher than AST and ALT levels.[2,3]
Patients who have obstructive jaundice due to a common bile
duct (CBD) stone generally exhibit the cholestatic pattern, with
relatively low aminotransferase levels.[4,5] Although some
patients with a CBD stone in combination with cholangitis
show marked elevation of aminotransferase levels, other CBD
stone patients exhibit elevated aminotransferase levels without
cholangitis,[6,7] which sometimes leads to the misdiagnosis of
liver diseases such as viral hepatitis, drug-induced hepatitis, or
ischemic liver injury. Therefore, clinical investigation of the
characteristics of patients with a CBD stone and markedly
elevated aminotransferase levels without the presence of
Table 1
Diagnostic criteria for acute cholangitis.
A. Clinical context and
clinical manifestations
1. History of biliary disease
2. Fever and/or chills
3. Jaundice
4. Abdominal pain (RUQ or upper abdominal)
B. Laboratory data 5. Evidence of inﬂammatory response
∗
6. Abnormal liver function tests†
C. Imaging ﬁndings 7. Biliary dilatation, or evidence of an etiology
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However, few studies of this patient population have been
conducted, and these studies are limited by their retrospective
nature and the fact that factors such as cholangitis, which can
affect aminotransferase levels, were not excluded.[8–11] The
aim of this prospective study was to characterize the clinicopath-
ologic features of patients with a CBD stone and markedly
elevated serum aminotransferase levels without the presence of
cholangitis.(stricture, stone, stent, etc.)
Suspected diagnosis Two or more items in A
Deﬁnite diagnosis (1) Charcot triad (2+3+4)
(2) Two or more items in A+both items in B and
item C
ALP= alkaline phosphatase, ALT= alanine aminotransferase, AST= aspartate aminotransferase,
CRP=C-reactive protein, g-GT=gamma-glutamyl transpeptideas, RUQ= right upper quadrant,
WBC=white blood cell count.
∗
Abnormal WBC count, increase of serum CRP level, and other changes indicating inﬂammation.
† Increased serum ALP, g-GT, AST, and ALT levels.2. Methods
2.1. Patients
Between June 2006 and June 2015, patients conﬁrmed to have a
CBD stone by endoscopic retrograde cholangiopancreatogra-
phy (ERCP) were enrolled in this study, which was conducted at
Gangnam Severance Hospital in Seoul, Korea. Patients with
underlying hepatobiliary disease such as viral hepatitis (i.e.,
hepatitis A, B, or C virus infection), autoimmune hepatitis,
hepatolithiasis, and liver cirrhosis, which can affect amino-
transferase levels, were excluded from analysis. Patients who
had cholangitis upon hospital admission, used hepatotoxic
agents or herbs or were alcoholics, previously had endoscopic
sphincterotomy, or who showed moderate elevations (38–399
IU/L) of aminotransferase levels were also excluded from
analysis (Fig. 1). According to the 2007 Tokyo guidelines
(Table 1), cholangitis was diagnosed if there were signs of
inﬂammation in laboratory test results or radiological images.
The remaining patients were divided into 2 groups; the gallstone
hepatitis (GSH) group consisted of patients with aminotrans-
ferase levels >400 IU/L upon hospital admission, and the
control group consisted of patients with normal AST (37 IU/L)
and ALT (46 IU/L) levels. In order to clarify the characteristics
of GSH, we deﬁned the control group as patients with normal
aminotransferase who were judged to have minimal liver
damage. This study was approved by the Institutional Review
Board at Gangnam Severance Hospital (approval number:Figure 1. Patient selection process. CBD=common bile duct, E
24-2012-0165) and registered at ClinicalTrials.gov (identiﬁer:
NCT02647593).
2.2. Data acquisition and procedures
Demographic and clinical variables, including gender, age,
symptoms (i.e., abdominal pain, duration, severity, and location),
radiologic ﬁndings (i.e., gallbladder distension, gallbladder
stones, and intrahepatic duct dilatation), ERCP ﬁndings (i.e.,
CBD diameter, diameter and number of CBD stones, and
periampullary diverticulum), and laboratory ﬁndings (i.e., white
blood cell count, levels of C-reactive protein, AST, ALT, total
bilirubin, ALP, g-GT, amylase, and lipase) were evaluated for
patients in the GSH and control groups. Abdominal pain severity
was measured by a numeric rating scale: no pain (0), mild pain
(1–3), moderate pain (4–6), or severe pain (7–10). LaboratoryST=endoscopic sphincterotomy, GSH=gallstone hepatitis.
Table 2





(N=116) (n, %) P
Age (years, mean±SD) 53.7±15.6 65.7±13.5 <0.001
Gender 0.262
Male 14 (36.8) 56 (48.3)
Female 24 (63.2) 60 (51.7)
Abdominal pain 37 (97.4) 51 (44.0) <0.001
Pain site 0.800
Epigastric area 25 (67.6) 32 (62.7)
RUQ area 12 (32.4) 19 (37.3)
Pain duration, hours <0.001
48 33 (89.2) 18 (35.3)
≥48 4 (10.8) 33 (67.7)
Pain score <0.001
Mild (1–4) 1 (2.7) 32 (62.8)
Moderate (5–6) 16 (43.2) 16 (31.4)
Severe (7–10) 20 (54.4) 3 (5.8)
Pancreatitis 3 (7.9) 4 (3.4) 0.365
GB stone 31 (81.6) 50 (43.1) <0.001
GB distension 9 (23.7) 18 (15.5) 0.325
CBD diameter (mm, mean±SD) 9.8±4.5 13.6±6.3 <0.001
CBD stone diameter, mm 0.192
<4 13 (34.2) 30 (25.9)
4–8 16 (42.1) 40 (34.5)
>8 9 (23.7) 46 (39.7)
CBD stone number 1.7±1.6 1.7±1.6 0.965
IHD dilation 10 (26.3) 39 (33.6) 0.431
Periampullar diverticulum 4 (10.5) 21 (18.1) 0.322
Laboratory ﬁndings
WBC, mL 8,322±3,578 7,560±3,058 0.203
CRP, mg/L 4.9±6.3 9.6±20.2 0.167
AST, IU/L 590.0±366.2 24.1±7.3 <0.001
ALT, IU/L 501.8±226.4 20.2±9.6 <0.001
Total bilirubin, mg/dL 2.4±1.6 0.8±0.8 <0.001
ALP, IU/L 501.8±226.4 20.2±9.7 <0.001
g-GT, IU/L 484.5±315.5 88.4±161.2 <0.001
Amylase, U/L 108.6±200.1 99.2±167.6 0.781
Lipase, U/L 155.3±496.0 104.2±403.9 0.536
ALP, normal values 39 to 111; ALT, normal values 11 to 46; AST, normal values 16 to 37; CRP,
normal values 0.1 to 6.0; g-GT, normal values 8 to 46; total bilirubin, normal value 0.3 to 1.8; WBC,
normal values 4000 to 10,800; amylase, normal values 25 to 97, lipase, normal values 6 to 46.
ALP= alkaline phosphatase, ALT= alanine aminotransferase, AST= aspartate aminotransferase,
CBD= common bile duct, CRP=C-reactive protein, GB=gallbladder, GSH=gallstone hepatitis,
g-GT=gamma-glutamyl transpeptideas, IHD= intrahepatic duct, RUQ= right upper quadrant, SD=
standard deviation, WBC=white blood cell count.
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before leaving the hospital.
Three endoscopists (DKL, SJL, and SIJ) who had performed
ERCP over 1000 times carried out the procedure using an
endoscopy system (TJF 240, Olympus, Tokyo, Japan).
Choleystectomywas performed for patients in both groups who
had gallbladder stones. Liver biopsy was performed for patients in
the GSH group who underwent elective cholecystectomy. Liver
tissue (36–7mm) was obtained using endoscopic scissors while
cholecystectomy was being performed in the operating room.
Hemorrhage sites were controlled using electrocautery.
2.3. Statistical analysis
Statistical analyses were performed using Student t tests and chi-
square tests. Multiple logistic regression analysis was used to
determine independent predictors of GSH. Statistical signiﬁcance3was set at P<0.05. All statistical analyses were performed using
SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL).3. Results
3.1. Demographic and clinical characteristics of the GSH
and control groups
A total of 882 patients had CBD stones conﬁrmed by ERCP
during the study period. Of these patients, 62 with underlying
hepatobiliary disease, 18 who used hepatotoxic agents or herbs
or were alcoholics, 39 who had endoscopic sphincterotomy or
recurrent CBD stones, 471 who had cholangitis upon hospital
admission, and 138 who showed moderate elevations of
aminotransferase levels were excluded, leaving 38 patients
(4.3%) in the GSH group and 116 patients (13.2%) in the
control group (Fig. 1). Ten patients in the GSH group were
misdiagnosed as having liver disease, resulting in the delay of
diagnosis and treatment such as ERCP. Also, 69 of the 882
patients (7.8%) were diagnosed with gallstone pancreatitis, and 3
patients (0.3%) were diagnosed with both GSH and gallstone
pancreatitis.
Patients in the GSH group were younger on average than
patients in the control group. Also, the incidence of abdominal
pain among patients in the GSH group was signiﬁcantly higher
than that among patients in the control group. Compared to
control patients, GSH patients had more moderate to severe
abdominal pain, classiﬁed as a score of 5 or higher, which lasted
for relatively short periods less than 48hours. There was no
signiﬁcant difference in the site of abdominal pain between
groups. Examinations such as abdomen ultrasonography or
abdominal computer tomography prior to ERCP showed that the
incidence of gallbladder stones was higher in GSH patients than
in control patients. ERCP showed that GSH patients had
narrower CBDs than control patients. Laboratory tests revealed
signiﬁcant differences between groups in AST, ALT, total
bilirubin, ALP, and g-GT levels, whereas white blood cell count
and levels of amylase, lipase, and C-reactive protein were similar
between groups (Table 2). The removal of CBD stones under
ERCP was associated with improved liver function test results at
discharge (Fig. 2).
3.2. Liver pathology
For 5 patients in the GSH group, liver biopsy was performed
during cholecystectomy an average of 11.2 days after hospital
admission. No patients showed any speciﬁc abnormalities except
minimal inﬂammatory changes (Fig. 3A and B).
3.3. Multivariate analysis
Multivariate logistic regression analysis showed that the
incidence, duration, and intensity of abdominal pain, the
presence of gallbladder stones, and age were independent risk
factors for GSH (Table 3).4. Discussion
We investigated the clinicopathologic features of patients with a
CBD stone and high aminotransferase levels without the presence
of cholangitis. Among 882 patients with CBD stones, 38 (4.3%)
were diagnosed with GSH, and these patients showed distinct
features such as severe and short-lasting abdominal pain,
Figure 2. AST and ALT levels at hospital admission and discharge for CBD
patients in the gallstone hepatitis group. The removal of CBDs was associated
with improved liver function test results at discharge. ALT=alanine
transaminase, AST=aspartate aminotransferase, CBD=common bile duct.
Table 3
Predictive factor of gallstone hepatitis in multivariate logistic
regression analysis.
Factors Odds ratio (95% CI) P
Age (<65 years vs ≥65 years) 5.212 (1.748–15.545) 0.003
Abdominal pain (yes vs no) 43.782 (5.537–346.171) 0.001
Pain duration (48 vs >48 hours) 7.821 (1.715–35.681) 0.008
Pain severity (moderate to severe vs mild) 41.101 (4.539–372.213) 0.001
GB stone (yes vs no) 4.208 (1.457–12.152) 0.008
CBD diameter (10 vs >10 mm) 1.205 (0.427–3.406) 0.724
CBD= common bile duct, CI= conﬁdence interval, GB=gallbladder.
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narrowCBDs as measured by ERCP. In patients with CBD stones
and aminotransferase levels 400IU/L who did not have
cholangitis, the AST level was 149.5±72.3 IU/L and the ALT
level was 183±91.3 IU/L. Age (59.8±17.3 years), CBD diameter
(14.5±7.8mm), and GB stone frequency (48.3%) showed no
signiﬁcant differences compared with the control group. The
difference in abdominal pain frequency (60.8%) was signiﬁcant
compared with the control group, but not the GSH group. No
difference was detected in pain duration or severity compared
with the control group. Therefore, none of the clinicopathologic
features evaluated were signiﬁcantly associated with the
moderately increased aminotransferase levels.
A previous study of patients with obstructive jaundice showed
that 98% and 93% of patients had AST and ALT levels lower
than 400IU/L, respectively, and less than 7% of patients had AST
or ALT levels higher than 400IU/L.[4,12] We found that 16.5% of
patients diagnosed with a CBD stone had aminotransferase levels
higher than 400IU/L, and 4.3% of CBD stone patients had high
serum levels of aminotransferases without the presence of
cholangitis (GSH group). Some patients had high levels ofFigure 3. Representative photomicrographs of liver tissue in gallstone hepatitis gro
Very mild portal inﬂammation (H&E stain, 200 magniﬁcation).
4aminotransferases but did not meet inclusion criteria for the GSH
group (12.2%). Although a GSH component may exist in these
patients, we excluded them from analysis to investigate the exact
clinical characteristics of GSH.
Levels of ALP and g-GT, which are considered cholestatic liver
enzymes, generally increase under conditions in which biliary
obstruction occurs. [2,3] Anciaux et al demonstrated that serum
ALP and g-GT were elevated within the 1st 3 days in 100% of
patients with biliary obstruction, whereas aminotransferase
levels were elevated in up to 88% of patients, with a mean of
102 to 150IU/L for AST and ALT.[13] Although a more dramatic
elevation in aminotransferase levels has been considered to be
indicator of choledocholithiasis, it is still unclear whether it
indicates acute hepatitis in clinical practice.[9,14] Nathwani et al
showed that among 478 patients with CBD stones, 2.3% had
normal aminotransferase levels, and 27.8%, 18.4%, and 9.6%of
patients had levels higher than 250, 500, and 1000IU/L,
respectively.[9] However, this report did not provide detailed
information such as presenting symptoms (e.g., cholangitis-
associated symptoms), ERCP ﬁndings, or the intensity and
pattern of abdominal pain. Also, previous studies did not rule out
cholangitis, which can affect aminotransferase levels.[8–11,15] In
the present study, however, we strictly excluded several factors
that can affect aminotransferase levels, including cholangitis.
In patients with biliary obstruction, the mechanism underlying
elevated serum aminotransferase levels remains unknown. In an
animal model, normal CBD hydrostatic pressure is 10 to 15cm
H2O (7.4–11mmHg), and nonsphincteric biliary obstruction
increases pressure to 25 to 40cm H2O (18–30mmHg).
[16,17] In
humans, CBD pressure is increased in biliary obstruction along
with an increase in the frequency of retrograde propagation of theup. (A) Very mild sinusoidal lymphocytosis (H&E stain, 200magniﬁcation). (B)
[10]
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hydrostatic pressure.[18,19] These changes also lead to increased
hepatocellular permeability, aminotransferase production, and
hepatocyte toxicity caused by bile acid, which in turn results in
increased aminotransferase levels.[20,21] When the bile duct is
occluded, hepatocytes undergo inﬂammatory damage. Previous
studies show that rats with bile duct ligation show not only
increased phagocytosis of Kupffer cells but also increased
production of several cytokines and platelet-activating
factor.[22–24] Additionally, activated neutrophils increase in
number and accumulate in the liver following bile duct ligation,
thus aggravating liver damage.[25–28]
Previous studies indicate that liver test results rapidly improve
after the removal of a CBD stone within 3 to 14 days in patients
with choledocholithiasis and marked elevation of aminotrans-
ferase levels.[9,11] The present study also shows that liver function
test results dramatically improved within a relatively short time
period after the removal of a CBD stone under ERCP. Also,
histological examination of liver biopsy tissue revealed only mild
inﬂammation in GSH patients. Given that the liver is an organ
capable of rapid recovery, our observations suggest that liver
recovery may occur more quickly if the removal of CBD stones is
timely executed.
Because the diameter of the bile duct is dilated in aged
individuals, compared with younger patients, bile duct pressure is
less elevated in aged patients with acute biliary obstruction which
may result in lower serum aminotransferase level.[29–32] Also,
elderly patients are less susceptible to pain than younger patients,
resulting in delayed hospital visit.[29,33,34] Furthermore, the
presence of gallbladder stones is thought to be a factor
contributing to the rapid elevation of CBD pressure through
gallstone migration. Primary choledocholithiasis progresses
slowly from stone formation to symptom expression to
anatomical changes caused by the stone, such as stone-induced
bile duct dilation. On the other hand, migrated secondary
gallstones can occlude distal CBDs without such changes, leading
to rapid increases in bile duct pressure. Retrograde pressure due
to increased bile duct pressure could possibly induce liver
parenchymal destruction with bilo-lymphatic and bilo-venous
reﬂux. Although the gallbladder could serve as a reservoir for the
sudden rise of intraductal pressure,[35] migrated stones and
edema of the cystic duct could disturb the role of the gallbladder
in buffering pressure. Thus, younger patients may exhibit
narrower CBDs and abrupt increases in intrabile duct pressure,
which could contribute to dramatically elevated aminotransfer-
ase levels and severe abdominal pain. Clinically, the drastic rise of
aminotransferase levels in patients with CBD stones can be
misdiagnosed as liver disease, which often results in the delay of
diagnosis and treatment. Given that abdominal pain is not the
main symptom of liver disease, and its intensity is low, this study
provides important evidence that severe abdominal pain is a clue
for differential diagnosis. Also, despite the elevated pressure
caused by ductal obstruction, we found that the incidence of GSH
(4.3%) was lower than that of gallstone pancreatitis (7.8%),
which could be due to anatomical differences in pancreatic and
bile ducts and buffering capability.
The term “gallstone hepatitis”was suggested in 1991 by Isogai
et al,[11] who deﬁnedGSH as consisting of severe abdominal pain,
marked elevated serum transaminase levels (≥300IU/L), and
gallstones, usually discovered in the dilated biliary tract,
including the by ultrasonography. At that point in time,
examinations using ERCP were not common, and CBD stones
tended to be managed conservatively in cases that were not5emergencies. Therefore, Isogai et al considered GSH as risk
factor for symptomatic bile duct stone or cholangitis. In contrast
to these previous studies,[10,11] we excluded patients with
cholangitis, which can increase aminotransferase levels, and
we compared GSH patients with control patients who had
normal aminotransferase levels. Therefore, we suggest a new
deﬁnition of “gallstone hepatitis” based on the clinicopathologic
features observed in our study.
Our study has several limitations. First, if liver biopsy is
performed at the time point when GSH is diagnosed, when
aminotransferase levels have reached their peak, the character-
istics of GSH could be conﬁrmed more accurately. However, this
was not done in the present study due to ethical consideration.
Therefore, our biopsy results are representative of the recovery
stage after acute liver injury, and they indicate complete livery
recovery after biliary decompression through endoscopic man-
agement. Second, we did not perform multiple deep biopsies but
rather a single biopsy in a superﬁcial and peripheral area of the
liver, which cannot reveal histological changes of the entire liver.
Third, a small number of patients in the GSH group underwent
liver biopsy; thus, the biopsy results might not be conﬁrmative.
Finally, because magnetic resonance cholangiopancreatography
and endoscopic ultrasound are not covered by insurance in our
country, they were not used as initial diagnostic tools. To our
knowledge, however, our study is the 1st to describe the
clinicopathologic characteristics of patients with a CBD stone
and marked aminotransferase elevation without cholangitis.
Furthermore, our study has the strengths of being a long-term,
prospective, single-center study.
In conclusion, patients in GSH group tended to be young and
experience moderate to severe abdominal pain lasting for
relatively short periods of time. Also, ERCP and radiologic
imaging showed narrow CBDs and gallbladder stone migration
in GSH patients. Taken together, we assume that marked
elevation of aminotransferase levels is induced under conditions
in which intrabile duct pressure dramatically surges. Also, these
clinical features can be helpful not only for differential diagnosis
with liver disease but also for investigating the underlying
mechanisms of liver damage in obstructive jaundice. Therefore,
we propose deﬁning “gallstone hepatitis” as the including: severe
abdominal pain, marked elevated of serum aminotransferase
levels (≥400IU/L), the conﬁrmation of a CBD stone through
various imaging techniques (e.g., abdomen ultrasonography,
abdominal computed tomography, and ERCP), the absence of
cholangitis, the exclusion of diseases or risk factors that increase
aminotransferase levels, and the rapid recovery of liver injury
after gallstone removal.
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